306 related articles for article (PubMed ID: 28923049)
1. Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.
Raju SV; Rasmussen L; Sloane PA; Tang LP; Libby EF; Rowe SM
Respir Res; 2017 Sep; 18(1):173. PubMed ID: 28923049
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
Lambert JA; Raju SV; Tang LP; McNicholas CM; Li Y; Courville CA; Farris RF; Coricor GE; Smoot LH; Mazur MM; Dransfield MT; Bolger GB; Rowe SM
Am J Respir Cell Mol Biol; 2014 Mar; 50(3):549-58. PubMed ID: 24106801
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast partially reverses smoke-induced mucociliary dysfunction.
Schmid A; Baumlin N; Ivonnet P; Dennis JS; Campos M; Krick S; Salathe M
Respir Res; 2015 Oct; 16():135. PubMed ID: 26521141
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.
Tyrrell J; Qian X; Freire J; Tarran R
Am J Physiol Lung Cell Mol Physiol; 2015 May; 308(10):L1068-77. PubMed ID: 25795727
[TBL] [Abstract][Full Text] [Related]
5. Vaporized E-Cigarette Liquids Induce Ion Transport Dysfunction in Airway Epithelia.
Lin VY; Fain MD; Jackson PL; Berryhill TF; Wilson LS; Mazur M; Barnes SJ; Blalock JE; Raju SV; Rowe SM
Am J Respir Cell Mol Biol; 2019 Aug; 61(2):162-173. PubMed ID: 30576219
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
8. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
9. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
10. Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis.
Raju SV; Tate JH; Peacock SK; Fang P; Oster RA; Dransfield MT; Rowe SM
Respir Res; 2014 Feb; 15(1):18. PubMed ID: 24517344
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.
Martorana PA; Beume R; Lucattelli M; Wollin L; Lungarella G
Am J Respir Crit Care Med; 2005 Oct; 172(7):848-53. PubMed ID: 15961691
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency.
Woodworth BA
Laryngoscope; 2015 Oct; 125 Suppl 7(0 7):S1-S13. PubMed ID: 25946147
[TBL] [Abstract][Full Text] [Related]
13. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast for COPD.
Izquierdo JL; Aparicio J
Drugs Today (Barc); 2010 Nov; 46(11):823-31. PubMed ID: 21225021
[TBL] [Abstract][Full Text] [Related]
15. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Sinopal'nikov AI
Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
[TBL] [Abstract][Full Text] [Related]
16. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast increases Clara cell secretory protein in cigarette smoke-exposed mice.
Ge XN; Chu HW; Minor MN; Case SR; Bosch DG; Martin RJ
COPD; 2009 Jun; 6(3):185-91. PubMed ID: 19811374
[TBL] [Abstract][Full Text] [Related]
18. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
20. Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen LF; Lv XD; Chen WY; Yang Q; Fang ZX; Lu WF
Ir J Med Sci; 2018 Aug; 187(3):731-738. PubMed ID: 29397527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
